Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure
Source: View publication →
The COMPANION trial demonstrated that in patients with advanced chronic heart failure and prolonged QRS intervals, cardiac-resynchronization therapy with or without an implantable defibrillator significantly reduced the combined risk of death or hospitalization compared to optimal pharmacologic therapy alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The COMPANION trial firmly established cardiac resynchronization therapy (CRT) as a cornerstone of treatment for advanced heart failure (NYHA class III/IV) in patients with a widened QRS complex and severe left ventricular systolic dysfunction. It proved that resynchronizing ventricular contraction improves both morbidity and mortality, particularly when combined with an implantable cardioverter-defibrillator (CRT-D), leading to strong guideline recommendations for biventricular pacing in patients with electrical dyssynchrony.
Historical Context
Prior to the COMPANION trial, optimal medical therapy was the standard for advanced heart failure. Although preliminary trials showed that biventricular pacing could improve hemodynamics and exercise capacity, its definitive impact on mortality and heart failure hospitalizations remained unproven. Published in 2004, COMPANION fundamentally expanded device-based interventions in cardiology by demonstrating that correcting electrical dyssynchrony definitively alters the natural history of the disease.
Guided Discussion
High-yield insights from every perspective
In patients with heart failure with reduced ejection fraction, what is the pathophysiological significance of a prolonged QRS duration, and how does cardiac resynchronization therapy (CRT) hemodynamically benefit these patients?
Key Response
A prolonged QRS (such as in left bundle branch block) indicates delayed and discoordinated left ventricular activation (electrical dyssynchrony). This leads to paradoxical septal motion, reduced stroke volume, increased wall stress, and worsened secondary mitral regurgitation. CRT uses biventricular pacing to restore synchronous ventricular contraction, thereby improving mechanical efficiency, increasing cardiac output, and promoting reverse ventricular remodeling.
Based on the COMPANION trial and subsequent data, how do you decide whether a patient with an LVEF of 25%, NYHA class III symptoms, and a LBBB with a QRS of 150 msec should receive a CRT-P (pacemaker) versus a CRT-D (defibrillator)?
Key Response
This patient clearly meets indications for CRT. The COMPANION trial showed that while CRT-P significantly reduces the combined endpoint of death or hospitalization, CRT-D significantly reduces all-cause mortality compared to medical therapy alone. The choice between CRT-P and CRT-D depends on factors like life expectancy (>1 year required for primary prevention ICD benefit), comorbidities, ischemic vs. non-ischemic etiology, and patient preference regarding defibrillator shocks.
The COMPANION trial included patients with any QRS prolongation >120 ms. Given subsequent subset analyses and later trials, how does the underlying QRS morphology (LBBB vs. non-LBBB) impact the expected magnitude of benefit from CRT, and how should a fellow approach the systematic evaluation of a CRT non-responder?
Key Response
Post-hoc analyses of early CRT trials and prospective data from studies like MADIT-CRT revealed that true LBBB morphology strongly predicts a robust clinical and echocardiographic response to CRT, whereas non-LBBB morphologies (RBBB, IVCD) derive much less or negligible benefit. For non-responders, fellows must evaluate for suboptimal LV lead placement, lack of continuous biventricular capture (due to frequent PVCs or atrial fibrillation), inadequate AV/VV delay programming, or progressive underlying structural disease.
While COMPANION highlighted a 36% mortality reduction for CRT-D, the CRT-P arm showed a strong trend toward mortality reduction and a significant drop in hospitalizations. In modern practice, when counseling an elderly, highly frail patient with advanced non-ischemic cardiomyopathy, how do you weigh the benefits of CRT-P versus CRT-D to optimize shared decision-making?
Key Response
The added benefit of the defibrillator (CRT-D) over a pacemaker (CRT-P) is solely the prevention of sudden arrhythmic death. In frail, elderly patients with significant competing non-cardiac mortality risks, preventing sudden death may not translate to a meaningful extension of high-quality life and exposes them to painful inappropriate shocks. CRT-P provides the hemodynamic benefits of improved symptoms and fewer hospitalizations without the burden of device shocks or the need for difficult end-of-life deactivation conversations.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The COMPANION trial utilized a composite primary endpoint of all-cause mortality or hospitalization for any cause. What are the statistical and methodological limitations of using such a broad composite endpoint in an unblinded device trial, and how do competing risks complicate the interpretation of the hospitalization component?
Key Response
Combining mortality and all-cause hospitalization treats a transient event equally with a terminal event in a time-to-first-event analysis. Furthermore, death acts as a competing risk for hospitalization (patients who die early cannot be hospitalized later), potentially skewing the rates. Additionally, in an unblinded trial, 'hospitalization for any cause' is susceptible to provider bias, as knowledge of the treatment allocation might influence the clinical threshold for admission.
As a critical reviewer of the COMPANION trial, what major threat to internal validity arises from the open-label design of the optimal pharmacologic therapy (OPT) control arm, particularly regarding the secondary endpoint of hospitalization?
Key Response
Because the trial lacked a sham procedure, it could not be blinded. Physicians and patients knew who received a device and who received only OPT. This lack of blinding is a major threat to validity because it can lower a clinician's threshold to hospitalize a patient in the OPT arm for heart failure symptoms, artificially inflating the hospitalization endpoint in the control group compared to the device arms where physicians might feel more secure managing patients as outpatients.
How did the COMPANION trial, alongside CARE-HF, establish the foundation for current ACC/AHA/HFSA guidelines regarding CRT, and how have modern guidelines refined the original broad COMPANION inclusion criteria (QRS > 120 ms) to formulate their Class 1 recommendations?
Key Response
COMPANION and CARE-HF provided the foundational evidence that CRT improves morbidity and mortality in advanced heart failure. Current ACC/AHA/HFSA guidelines award a Class 1 (Level of Evidence: A) recommendation for CRT. However, guidelines refined the broad COMPANION criteria based on subsequent evidence: a Class 1 recommendation now strictly requires LVEF <= 35%, sinus rhythm, LBBB morphology, and a QRS duration >= 150 ms, reflecting that the most profound benefit is seen in this specific phenotype rather than any QRS > 120 ms.
Clinical Landscape
Noteworthy Related Trials
CARE-HF Trial
Tested
Cardiac resynchronization therapy without defibrillator (CRT-P)
Population
Patients with NYHA class III or IV heart failure, reduced ejection fraction, and ventricular dyssynchrony
Comparator
Standard pharmacological therapy alone
Endpoint
Composite of death from any cause or unplanned hospitalization for a major cardiovascular event
MADIT-CRT Trial
Tested
Cardiac resynchronization therapy with defibrillator (CRT-D)
Population
Patients with mild heart failure (NYHA class I or II), reduced ejection fraction, and wide QRS complex
Comparator
Implantable cardioverter-defibrillator (ICD) alone
Endpoint
Composite of death from any cause or a nonfatal heart-failure event
RAFT Trial
Tested
Cardiac resynchronization therapy with defibrillator (CRT-D)
Population
Patients with NYHA class II or III heart failure, reduced ejection fraction, and wide QRS complex
Comparator
Implantable cardioverter-defibrillator (ICD) alone
Endpoint
Composite of death from any cause or hospitalization for heart failure
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis